Drug Trial Radar · NCT06427291
Clinical Study of T3011 Intravesical Instillation for Treatment of NMIBC Patients
Last checked: Nov 19, 2026Latest source record: May 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 21, 2023
Primary completion
Dec 31, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- Fudan UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 23, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label, single-arm investigator-initiated clinical study. It is used to evaluate the safety and efficacy of T3011 intravesical instillation in patients with BCG-failure high-risk non-muscle invasive bladder cancer (NMIBC)
Conditions
- Bladder Cancer
Interventions
Herpes virus T3011 injectionBiological
T3011 will be instilled in the entire solution volume of 50ml, and be will be left in the bladder for at least 1 hour, no more than 2 hours. After competing instillation, the patients should be instructed to drink at lest 1000mL of water
Primary outcomes
What the sponsor says the trial is designed to measure.
- CR rate or relapse-free survival rates at 3, 6, 9 and 12 months after the first study doseTime frame: 3, 6, 9 and 12 months after first study dose
- Recurrence-free survival, RFSTime frame: Up to 2 years
- Progression-free survival, PFSTime frame: Up to 2 years
- Incidence of radical cystectomyTime frame: Up to 2 years
- 5-year survival rateTime frame: Up to 5 years
- Adverse Events, AETime frame: up to 30 days after completion of treatment
- Serious Adverse Event, SAETime frame: up to 30 days after completion of treatment
- Dose-limiting toxicity (DLT) eventsTime frame: First cycle of treatment, i.e. within 28 days of first instillation
- Abnormal clinically significant vital signs and their incidenceTime frame: Up to 1 years
- Abnormal clinically significant physical findings and their incidenceTime frame: Up to 1 years
- Abnormal clinically significant laboratory findings and their incidenceTime frame: Up to 1 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.